Background: The timing and mechanisms of asthma inception remain imprecisely defined. Although epigenetic mechanisms likely contribute to asthma pathogenesis, little is known about their role in asthma inception. Objective: We sought to assess whether the trajectory to asthma begins already at birth and whether epigenetic mechanisms, specifically DNA methylation, contribute to asthma inception. Methods: We used the Methylated CpG Island Recovery Assay chip to survey DNA methylation in cord blood mononuclear cells from 36 children (18 nonasthmatic and 18 asthmatic subjects by age 9 years) from the Infant Immune Study (IIS), an unselected birth cohort closely monitored for asthma for a decade. SMAD3 methylation in IIS (n 5 60) and in 2 replication cohorts (the Manchester Asthma and Allergy Study [n 5 30] and the Childhood Origins of Asthma Study [n 5 28]) was analyzed by using bisulfite sequencing or Illumina 450K arrays. Cord blood mononuclear cell-derived IL-1b levels were measured by means of ELISA. Results: Neonatal immune cells harbored 589 differentially methylated regions that distinguished IIS children who did and did not have asthma by age 9 years. In all 3 cohorts methylation in SMAD3, the most connected node within the network of asthma-associated, differentially methylated regions, was selectively increased in asthmatic children of asthmatic mothers and was associated with childhood asthma risk. Moreover, SMAD3 methylation in IIS neonates with maternal asthma was strongly and positively associated with neonatal production of IL-1b, an innate inflammatory mediator. Conclusions: The trajectory to childhood asthma begins at birth and involves epigenetic modifications in immunoregulatory and proinflammatory pathways. Maternal asthma influences epigenetic mechanisms that contribute to the inception of this trajectory. (J Allergy Clin Immunol 2017;140:534-42.)
Key words: Epigenetics, DNA methylation, childhood asthma, SMAD3 Asthma is the most prevalent chronic disease of childhood. 1 Epidemiologic evidence suggests that the disease often begins during the preschool years, even when chronic symptoms appear much later in life. 2 However, firm criteria to pinpoint how early a child's trajectory to asthma truly begins are currently lacking. The mechanisms underlying asthma inception also remain largely unknown. Subtle modifications of both innate and adaptive immune responses accompany and often precede the diagnosis of childhood asthma, 3, 4 which is consistent with the notion that immune and respiratory alterations at an early window of susceptibility converge to place the child on a path to the disease.
Genome-wide association studies (GWASs) have identified multiple genetic variants that influence asthma susceptibility 5 but have accounted for only a modest proportion of the total phenotypic variance, providing a compelling rationale for seeking additional risk factors for asthma. In this context epigenetic mechanisms are especially worth investigating because Received for publication February 26, 2016 1 and epigenetic processes ensure the timed unfolding of developmental programs and plastic responses to environmental cues, including those delivered in utero by the maternal milieu. 6 Little is known about the role of epigenetic mechanisms in childhood asthma. 7 A recent epigenome-wide study compared DNA methylation patterns in PBMCs from 6-to 12-year-old inner-city children with persistent atopic asthma and healthy control subjects and found that several immune genes involved in T-cell maturation, T H 2 immunity, and oxidative stress were hypomethylated in asthmatic children. 8 Although these results are novel, their significance remains unclear because it is difficult to determine whether epigenetic alterations concurrent with asthma are a cause or a consequence of the disease. Moreover, a cross-sectional study cannot provide insights into the timing and mechanisms of asthma inception. A recent candidate gene study pointed to an association between IL2 promoter methylation at birth and asthma exacerbations during childhood, 9 but relevant pathways were not interrogated further.
In an attempt to define when the trajectory to asthma begins and which pathways are involved, we performed an epigenome-wide search for DNA methylation signatures associated with childhood asthma in cord blood mononuclear cells (CBMCs) from children enrolled in the Infant Immune Study (IIS). In this unselected birth cohort the development of asthma and immune responses was monitored at multiple times from birth to age 9 years. 4, 10 We reasoned that the detection at birth of differentially methylated regions (DMRs) associated with asthma during childhood would both support a perinatal origin of the disease and highlight epigenetic mechanisms potentially contributing to asthma inception.
Here we show that DNA methylation signatures associated with asthma during childhood were indeed present in neonatal blood immune cells and clustered in immunoregulatory and proinflammatory pathways. Moreover, hypermethylation of the SMAD3 promoter was selectively detected in asthmatic children of asthmatic mothers and was associated with risk of childhood asthma in the IIS population and in 2 comparable birth cohorts.
METHODS

Study design and participants
The IIS unselected birth cohort includes 482 children and was designed to assess patterns of immune maturation in early life and their effect on asthma J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 2 risk. 4, 10 At enrollment, parents completed a respiratory health history questionnaire, a cord blood sample was obtained, and the child's health was followed prospectively. Childhood asthma was defined as physician diagnosed, with symptoms or medication use for asthma in the past year reported at least once on the age 2-, 3-, 5-, or 9-year questionnaires. Fig 1 shows an overview of our study design. We performed a nested casecontrol, epigenome-wide study of DNA methylation in CBMCs (2-8 3 10 6 cells per sample) from a discovery population of 36 children from the IIS. This population was randomly selected among available samples but balanced for asthma status in the child (18 nonasthmatic and 18 asthmatic subjects by age 9 years), and an effort was made to balance cases and control subjects by maternal asthma (see Table E1 in this article's Online Repository at www.jacionline.org). Additional targeted analysis of DNA methylation was performed in the 31 samples available from the IIS discovery population and in samples from 29 additional IIS children with comparable characteristics (see Table E2 in this article's Online Repository at www.jacionline.org). The distribution of cases and control subjects is provided in Fig 1. Availability of adequate samples was the only inclusion criterion besides asthma status of the child and her or his mother. Overall, the study population did not differ from the rest of the IIS population, except for a greater proportion of asthma and maternal asthma, as per study design (see Table E1 ).
The results of targeted DNA methylation analysis performed in the IIS were replicated in CBMCs from 30 children with asthmatic mothers from the Manchester Asthma and Allergy Study (MAAS) and 28 children from the Childhood Origins of Asthma (COAST) study (Fig 1) . The characteristics of the MAAS and COAST study populations are described in Table E2 . The MAAS unselected birth cohort includes 1085 children monitored for asthma and allergy from birth to age 11 years. An asthma diagnosis required at least one of the following criteria reported on age 5-or 8-year questionnaires: (1) physician's diagnosis of asthma and (2) use of asthma medications during the previous 12 months. Control subjects required a negative report on both of these criteria and no report of wheezing in the previous 12 months. 11 The COAST birth cohort enrolled 289 neonates at risk for asthma and allergy (ie, having > _1 parent with asthma, allergies, or both). Asthma was diagnosed at age 6 years based on the documented presence of 1 or more of the following characteristics in the previous year: (1) physician's diagnosis of asthma; (2) use of physician-prescribed albuterol for coughing or wheezing episodes; (3) use of a daily controller medication; (4) step-up plan, including use of albuterol or short-term use of inhaled corticosteroids during illness; and (5) use of prednisone for asthma exacerbations. 12 All 3 studies were approved by the appropriate institutional review boards. Informed consent was obtained from the parents of all research participants. jacionline.org. DNA methylation microarray data from this publication were submitted to the National Center for Biotechnology Information Gene Expression Omnibus database and assigned the identifier GSE85228.
DNA methylation profiling and DMR identification
Regions that were differentially methylated between asthmatic and nonasthmatic subjects (DMRs) were identified by using a probe sliding window ANOVA (Roche-NimbleGen) 13 that detects maximal intergroup differences in signal intensities relative to a user-defined threshold. Probability scores (P values) are then assigned to each probe on the array by using a repeatedmeasures ANOVA model. In this study DMRs were defined by a region length of 300 bp or greater, a magnitude (between-group mean log 2 ratio difference) of 0.2 or greater, and a significance threshold (adjusted by using the Benjamini-Hochberg false discovery rate method to account for multiple testing) of 0.01 by using a sliding window size of 750 bp (see Table E3 in this article's Online Repository at www.jacionline.org). A positive magnitude difference indicated hypermethylation in asthmatic relative to nonasthmatic subjects. DMRs containing 5 or fewer CpG sites within a 750-bp window centered on the DMR (a configuration likely to result in suboptimal capture of methylated DNA) 14 were excluded from further analyses. Results of this analysis were technically validated by means of bisulfite sequencing (see the Methods section and Table E4 in this article's Online Repository at www.jacionline.org). Microarray-derived estimates of DNA methylation intensity strongly correlated with DNA methylation levels measured by using bisulfite sequencing over the entire DNA methylation range (Spearman correlation coefficient [r] 5 0.48, P 5 1.2 3 10
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) and at intermediate DNA methylation levels (8% to 92%, P 5 .006; see Fig E2 in this article's Online Repository at www.jacionline.org). SMAD3 methylation estimates from bisulfite sequencing and microarrays were also highly correlated (r 5 0.46, P 5 .009).
Functional DMR annotation is fully described in the Methods section in this article's Online Repository. In brief, DMRs were annotated to genes based on the closest transcription start site. For pathway analysis, multiple genes were allowed to be associated with a single DMR (RefSeq genes 65 kb).
DNA methylation analysis in the COAST cohort was performed by using the Infinium HumanMethylation450 BeadChip array (Illumina, San Diego, Calif; see the Methods section in this article's Online Repository).
Network analysis
A molecular interaction network was constructed by uploading the list of DMR-containing genes into the Ingenuity Pathway Analysis software (Qiagen, Hilden, Germany) and using all available interaction data in the Ingenuity Systems Knowledge Base. Genes with no interactions were removed from the analysis to maximize the signal-to-noise ratio. The gene interaction network was then interrogated to detect enrichment for biological functions, canonical pathways, and upstream regulators (defined as an enrichment for known targets of a given gene in a given gene list) by using Ingenuity Pathway Analysis tools.
Cytokine measurements
IL-1b concentrations were measured by means of ELISA (Quantikine; R&D Systems, Minneapolis, Minn) in supernatants of LPS-stimulated IIS CBMCs (n 5 57) also tested for SMAD3 promoter methylation.
Statistical analyses
DMRs were detected by using a probe sliding window ANOVA, which uses a repeated-measures ANOVA model for the probes in each sliding window. 13 The Fisher exact test and 1-sample test of proportions were used to compare proportions for categorical variables, and the Student t test or Wilcoxon 2-sample test was used to compare mean levels for continuous variables. Variables with skewed distributions were log-transformed before assessment by using the t test. Two-sided P values of less than .05 were considered significant. Spearman correlation was used to test for association between median DNA methylation intensity (microarray) and percentage of DNA methylation (bisulfite sequencing).
When analyzing the genomic locations of DMRs and the colocalization of DMRs and DNase I-hypersensitive sites, permutations were performed by randomly selecting 589 independent probes (the number of DMRs) and calculating the x 2 statistic for each sampling. We recorded the number of times (of 50,000) that the permuted x 2 statistic was larger than the observed x 2 statistic and divided by the number of permutations to obtain the empirical P value. Linear regression was used to test for an interaction between child and maternal asthma on SMAD3 methylation. The Pearson x 2 test was used to identify significant associations between child and parental characteristics at birth and asthma during childhood. Meta-analysis of the association between SMAD3 CpG7 methylation and childhood asthma risk in neonates born to asthmatic mothers was performed by using estimates from each study cohort to compute the combined estimate of risk.
RESULTS
Cord blood cells from IIS children harbor asthmaassociated DMRs
Our multistep study of the contribution of epigenetic mechanisms to the development of asthma in early life included (1) a discovery phase in which an epigenome-wide approach was used to identify candidate regions that were differentially methylated in cord blood samples from 36 IIS children (18 nonasthmatic and 18 asthmatic subjects by age 9 years); (2) a targeted analysis phase in which DNA methylation of the most compelling candidate region was measured in CBMCs from 29 IIS neonates who did and 31 IIS neonates who did not have asthma by age 9 years; and (3) a final phase in which the results of the targeted analysis performed in IIS were replicated in 2 comparable birth cohorts: MAAS and COAST (Fig 1) .
Relying on the longitudinal design of the IIS birth cohort, we initially searched for neonatal epigenetic signatures of childhood asthma by profiling DNA methylation in CBMCs from a discovery cohort of 36 children (Fig 1 and see Fig E1 and Table  E1 ). Five hundred eighty-nine independent regions were differentially methylated in asthmatic and nonasthmatic children (see Table E3 ). Among these, 199 were hypermethylated and 390 were hypomethylated at birth in children who became asthmatic.
Asthma-associated DMRs were distributed across all chromosomes but were nonrandomly distributed with respect to genome location ( ; 2log 10 adjusted P value 5 5.569), OR6K6 (an olfactory receptor expressed in sputum during asthma exacerbations 16 ; 2log 10 adjusted P 5 4.408), and GALNT2 (an N-acetylgalactosaminyltransferase carrying polymorphisms associated with lung function 17 ; 2log 10 adjusted P 5 4.895). Moreover, several asthma-associated DMRs mapped to loci (65 kb from transcription start sites) identified in GWASs for asthma (RORA and SMAD3) and asthma-related traits, such as atopic dermatitis (FLG), allergic rhinitis (TMEM232), lung function (ANK1, DLEU7, SNRPN, RORA, and CFDP1), and airflow obstruction (SPATA13; http://www.ebi.ac.uk/gwas). Functional annotation by using Ingenuity Pathway Analysis linked DMR-associated genes to biological processes, including immune function and immune and lung development (see Table  E5 in this article's Online Repository at www.jacionline.org). We also mapped the locations of neonatal asthma-associated DMRs to DNase I-hypersensitive sites, regions of increased chromatin accessibility typically endowed with regulatory activity. 18 Overall, 72 asthma-associated DMRs mapped to DNase I-hypersensitive sites (29 monocyte specific, 15 T cell specific, 28 in both cell types; see Table E6 in this article's Online Repository at www.jacionline.org), which represented a significant enrichment (permutation P < 2 3 10 25 for both cell types; see Table E7 in this article's Online Repository at www.jacionline. org). The colocalization of asthma-associated differential DNA methylation and enhanced chromatin accessibility supports the potential biological significance of asthma-associated DMRs.
Asthma-associated DMRs cluster in regulatory and proinflammatory gene networks
Ingenuity Pathway Analysis tools were used to construct a molecular interaction network of DMR-associated genes on the J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 2 basis of prior knowledge of the physical and functional connections between the molecules encoded by those genes to elucidate the functional implications of our findings and gain a pathwaybased view of asthma-associated methylome alterations at birth. The network included 146 genes organized around several nodes, the most connected of which was the transcription factor SMAD3 (Fig 2) . When the network was interrogated to detect enrichment for known targets of upstream regulators, IL1B, an innate proinflammatory cytokine overexpressed in asthmatic patients, [19] [20] [21] emerged as the top regulator of a gene subset that included RORA and RELB, transcription factors essential for innate and adaptive responses; UBD, an innate immunity gene regulated by the nuclear factor kB inhibitor A20/TNFAIP3 22 ; and the asthma-associated neurotrophin BDNF 19 (overlap P 5 2.26 3 10
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, Table I ).
SMAD3 promoter is significantly hypermethylated in asthmatic children of asthmatic mothers SMAD3 is not only the most connected node in the network of asthma-associated DMRs (Fig 2) but is also a well-replicated asthma-associated gene from GWASs. [23] [24] [25] Moreover, SMAD3 acts as a master regulator of TGF-b signaling, thereby controlling the differentiation of regulatory T (Treg) and T H 17 cells, which play critical and opposite roles in asthmatic patients. 1, 26 Finally, the SMAD3 DMR lies within the distal promoter of the gene, a location that provides ample opportunity for DNA methylation to influence SMAD3 gene expression (see Fig E4 in this article' s Online Repository at www.jacionline.org). Therefore subsequent analyses of the nexus between neonatal DNA methylation and trajectory to childhood asthma specifically targeted SMAD3. We used bisulfite sequencing to precisely quantify methylation at the SMAD3 promoter DMR (321 bp, 8 consecutive CpG sites) in a total of 60 IIS neonates (31 nonasthmatic and 29 asthmatic subjects, Fig 1) . Mean SMAD3 methylation levels at birth were 41.3% (95% CI, 35.5% to 47.5%) in nonasthmatic subjects and 47.1% (95% CI, 40.6% to 53.1%) in asthmatic subjects, a difference that did not reach statistical significance (P 5 . Because these results might have reflected heterogeneity within the study population, we next examined the entire IIS population for associations between childhood asthma and potential risk factors measurable at birth in the child (sex, ethnicity, mode of delivery, total cord IgE level, and 17q21 rs8076131 genotype) and parents (maternal asthma, maternal allergy, paternal asthma, paternal allergy, and maternal smoking during pregnancy). As shown in Table E8 in this article's Online Repository at www.jacionline.org, maternal asthma exhibited a distinctive association with childhood asthma in IIS (P 5 .003, x 2 test). When the relation between SMAD3 methylation at birth and childhood asthma was examined separately in children with and without maternal asthma, SMAD3 methylation was found to be significantly increased in asthmatic compared with nonasthmatic children of asthmatic mothers (P 5 .005, Wilcoxon 2-sample test). In contrast, asthmatic and nonasthmatic children of nonasthmatic mothers did not differ in their SMAD3 methylation levels (P for interaction [by linear regression] 5 .001; Fig 3, A) .
Although associations between SMAD3 variants (rs17228058, 25 rs744910, 23 and rs17294280 24 ) and asthma have been reported in GWASs, asthma-related SMAD3 methylation differences were unlikely to be influenced by SMAD3 genotype. Indeed, sequencing identified no polymorphisms within the SMAD3 DMR (data not shown). Moreover, asthma-associated SMAD3 variants are located at least 80 kb away from the SMAD3 DMR, whereas the relationship between DNA methylation and genetic variation appears to decay rapidly beyond 5 kb. 27 Association between SMAD3 promoter hypermethylation and childhood asthma replicates in 2 independent birth cohorts The association between neonatal SMAD3 hypermethylation and childhood asthma found in IIS neonates born to asthmatic mothers was assessed for replication in 2 birth cohorts: MAAS and COAST (see Table E2 ). Bisulfite sequencing of the SMAD3 DMR in 30 MAAS children born to asthmatic mothers revealed significantly higher DNA methylation in the asthmatic group (P 5 .049, Wilcoxon 2-sample test; Fig 3, B) . Comparable results were obtained by assessing SMAD3 methylation in 28 COAST neonates with the Illumina Infinium HumanMethylation450 BeadChip array. Fig 3, C, shows that methylation at cg02486855, the seventh CpG in the SMAD3 DMR and the only SMAD3 DMR CpG interrogated on the Illumina platform, did not significantly differ between asthmatic and nonasthmatic children of nonasthmatic mothers (P 5 .4, Wilcoxon 2-sample test). In contrast, significant cg02486855 hypermethylation was detected in neonates born to asthmatic mothers who had asthma during childhood compared with neonates who did not (P 5 .04, Wilcoxon 2-sample test; Fig 3, C) . The data generated by means of bisulfite sequencing and on the Illumina platform were comparable because when percentage methylation values for SMAD3 CpG7 were extracted from the bisulfite sequencing data for IIS and MAAS, again we found significant hypermethylation in asthmatic compared with nonasthmatic children of asthmatic mothers in IIS (P 5 .004, Wilcoxon 2-sample test; see Fig  E6 in this article's Online Repository at www.jacionline.org) and a difference approaching significance in MAAS (P 5 .09, Wilcoxon 2-sample test; see Fig E6) .
Cord blood contains a mixture of cell types with potentially distinct DNA methylation profiles. The availability of COAST DNA methylation data generated on the Illumina450 BeadChip array allowed us to estimate cord blood cell proportions by using an algorithm recently developed that integrates Illumina DNA methylation data with information from a cord blood reference panel. 28 Fig E7 in this article's Online Repository at www. jacionline.org shows that cell proportions thus estimated did not significantly differ between asthmatic and nonasthmatic children, regardless of maternal asthma history. Most importantly, the SMAD3 methylation differences detected between asthmatic and nonasthmatic children of asthmatic mothers remained significant (P 5 .04, Wilcoxon 2-sample test), even after adjusting for CBMC composition (see Fig E8 in this article' s Online Repository at www.jacionline.org).
Finally, we asked whether the SMAD3 methylation levels measured at birth in children of asthmatic mothers are associated with risk for childhood asthma in our 3 cohorts. A meta-analysis revealed that for each 10% increase in SMAD3 CpG7 methylation, there is a nearly 2-fold increased risk of childhood asthma (meta-analysis odds ratio, 1.95; 95% CI, 1.23-3.10; P 5.005; heterogeneity P 5 .5).
Maternal asthma modifies the relation between neonatal SMAD3 methylation and IL-1b-producing capacity SMAD3 knockout mice exhibit increased expression of Il1b, 29 which is also the top upstream regulator of genes containing asthma-associated DMRs in this study and a critical proinflammatory mediator in human asthma.
19-21 Therefore we relied again on the IIS to explore the relationship between neonatal LPS-induced IL-1b production, SMAD3 promoter methylation, and childhood asthma. The distributions of SMAD3 methylation and log IL-1b production in nonasthmatic and asthmatic children without and with a maternal history of asthma were compared by dividing mean percentage SMAD3 methylation and log IL-1b secretion at the median, thereby creating 4 groups (low/low, low/high, high/low, and high/high). No distribution differences were observed among children of nonasthmatic mothers (P 5 .79, Fisher exact test; Fig 4, A) . In contrast, the children of asthmatic mothers who had asthma were almost entirely found among those with high SMAD3 promoter methylation and high IL-1b secretion (P 5 .009, Fisher exact test; Fig 4, B) . Moreover, asthmatic children of asthmatic mothers had higher LPS-induced IL-1b than nonasthmatic children (P 5 .03, Student t test), whereas comparable IL-1b levels were measured in children without a maternal history of asthma (P 5 .65, Student t test; Table II ). These results suggest that a strong relationship exists between neonatal SMAD3 methylation, production of the innate cytokine IL-1b, and childhood asthma. Furthermore, our data suggest that this relationship is powerfully influenced by maternal asthma.
DISCUSSION
Although asthma is the most common chronic complex disease of childhood, 1 the timing and mechanisms of its inception remain largely unknown. This gap in knowledge severely hinders efforts aimed at preventing this disease, which no therapeutic regimen , and COAST (C). SMAD3 methylation in IIS and MAAS was assessed by means of bisulfite sequencing and expressed as a mean percentage of DNA methylation across 8 consecutive CpG sites in the SMAD3 DMR. In COAST percentage SMAD3 methylation at cg02486855, the seventh CpG in the SMAD3 DMR, was assessed by using the Infinium HumanMethylation450 BeadChip array. A, Asthmatic; N, nonasthmatic. P values were determined by using the Wilcoxon 2-sample test. Results presented in Fig 3, A, were unaffected after adjusting for ethnicity.
FIG 4.
Effects of maternal asthma on the relation between neonatal SMAD3 methylation and IL-1b protein production. Distributions of SMAD3 methylation and log IL-1b-producing capacity in nonasthmatic and asthmatic children without and with a maternal history of asthma were compared by dividing mean percentage SMAD3 methylation and log IL-1b secretion at the median, thereby creating 4 groups (low/low, low/high, high/low, and high/high). Distributions for asthmatic and nonasthmatic subjects were compared across all 4 quadrants (A) or focusing the analysis on the high/high and low/low quadrants (B; P value determined with the Fisher exact test). A, Asthmatic; N, nonasthmatic.
can currently cure. Our study, the first epigenome-wide search for asthma-associated methylome signatures at birth, sheds new light on these critical but still open questions. The finding that almost 600 genomic regions were differentially methylated at birth between children who did and did not have asthma later in life strongly suggests that the trajectory to asthma begins at birth, if not prenatally, and involves epigenetic mechanisms. As importantly, data from 3 birth cohorts showed that SMAD3 promoter hypermethylation was associated with childhood asthma selectively in neonates with a maternal history of asthma, one of the strongest and mechanistically one of the most elusive risk factors for asthma in the child. 30, 31 These findings are especially noteworthy in the context of the current dearth of characteristics measurable at birth that effectively predict asthma during childhood. Of note, the link between epigenetic SMAD3 dysregulation at birth and childhood asthma appeared to be selective for neonates born to asthmatic mothers, a finding that suggests that heterogeneity is deeply embedded in the pathogenesis of and trajectory to childhood asthma. 1, 32 More generally, to our knowledge, this is the first time that a neonatal epigenetic characteristic linked to asthma during childhood is robust enough to replicate across 3 independent birth cohorts.
Our study highlighted SMAD3 and IL-1b as main players in the trajectory to childhood asthma. SMAD3, the most connected node in the network of asthma-associated DMRs, is known to be critical for the regulation of both the asthma-protective Treg cell and the asthma-promoting T H 17 cell differentiation programs. Altered Treg and T H 17 cell activities have been reported in childhood asthma, 1, 26 and conversely, maternal exposure to asthma-protective environments, such as farming, has been shown to activate the Treg cell compartment 33 and influence the expression of T H 17 markers. 34 On the other hand, IL-1b, which emerged as the primary upstream regulator of genes harboring asthma-associated DMRs, is increasingly recognized as a key asthma mediator in both children 20 and adults, especially in those with neutrophilic asthma. 19, 21 Our data emphasize the functional connection between SMAD3 and IL-1b. Indeed, in neonates who became asthmatic by age 9 years, SMAD3 promoter hypermethylation, an epigenetic configuration consistent with low SMAD3 expression, was strongly associated with high IL-1b production. This convergence is likely to destabilize the Treg cell program, enhance inflammation, and promote T H 17 differentiation, 35 ultimately favoring the development of asthma. Although it is unclear whether these mechanisms operate prenatally and/or perinatally, detection of the relationship between SMAD3 methylation and IL-1b production selectively among children of asthmatic mothers implies that the in utero environment is critical for directing the epigenetic trajectory toward childhood asthma.
Our results should be interpreted with caution because our discovery population was small, although longitudinally phenotyped for asthma in great detail, and environmental exposures were not comprehensively assessed. Moreover, DNA methylation did not distinguish between 5-methylcytosine and other cytosine modifications and was assessed in mixed rather than isolated cell populations. However, our data from the COAST population suggest that differential methylation by asthma status did not reflect asthma-associated differences in CBMC proportions.
We also acknowledge that the DNA methylation differences we detected were not extreme, although more substantial than those recently reported in other studies. 8, 36 This is a recurring theme in the literature, 37 and systematic studies are needed to comprehensively assess how relatively modest DNA methylation differences modify disease trajectories. In general, the functional effect of such differences will likely depend on the regulatory properties of the locus in which they reside and the extent to which additional epigenetic processes, such as posttranslational histone modifications, influence those properties.
Gene expression analyses are often used to complement epigenetic studies, but samples for such analyses were not collected at birth in our study populations. On the other hand, samples for cytokine protein assessments were available and proved essential to integrate our epigenetic findings. Finally, our search for asthma-associated differential methylation returned almost 600 regions, only some of which mapped to genes involved in immunoregulation and inflammation. DMRs that reside in functionally interesting genes but lack a link to immune regulation or inflammation might also contribute to asthma pathogenesis, although through different mechanisms. With these caveats, we propose that in a proportion of children with childhood-onset asthma, a distinctive methylome is in place already at birth, particularly within innate immunoregulatory and proinflammatory pathways, and promotes a trajectory that might ultimately lead to clinical disease. Some of the epigenetic mechanisms that contribute to the inception of this trajectory are strongly influenced by the milieu associated with maternal asthma. A scenario in which epigenetic modifications at an early window of susceptibility promote a long-term developmental trajectory to asthma is consistent with the emerging paradigm that chronic noncommunicable diseases have their origins in early life through an epigenetic calibration of set points for later responsiveness and function. 38, 39 We thank the children and their parents for their continued support and enthusiasm; we greatly appreciate the commitment they have given to the project. We also acknowledge the hard work and dedication of the study team (postdoctoral scientists, research fellows, nurses, physiologists, technicians, and clerical staff). *Physician diagnosed with symptoms or medication use for asthma in the past year reported at least once on the age 2-, 3-, 5-, or 9-year questionnaires. Student t test after log 10 transformation.
Key messages
d The trajectory to childhood asthma begins at birth and involves epigenetic modifications in innate proinflammatory and immunoregulatory pathways.
d Neonatal immune cells collected at birth harbor DMRs that distinguish children who will and will not have asthma by age 9 years.
d In 3 independent birth cohorts DNA methylation at the SMAD3 promoter was selectively increased in asthmatic children of asthmatic mothers and was associated with risk of childhood asthma.
